This test requires professional lab infrastructure and staff and must be ordered and administered by medical professionals. The test cannot be performed by private individuals and we do not sell the kits to such subjects. If you suspect you are infected with SARS-CoV-2, please contact your healthcare provider.
Module based Enzyme Immunoassay for the confirmation of positive IgG antibodies against SARS coronavirus 2 (SARS-CoV-2) in the first screening. The test determines the specificity of antibodies against the main immunodominant antigens (Spike Glycoprotein 1, Spike Glycoprotein 2, Nucleocapsid) of SARS-CoV-2 in human serum or plasma.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously known as “2019-nCoV) is a zoonotic single-stranded RNA virus with positive polarity, belonging to the coronaviruses family. It is classified in the genus beta-coronavirus, which also includes SARS-CoV (2003) and MERS-CoV (2012). Among the coronavirus structural proteins envelope, membrane, spike and the nucleocapsid, the last two are the main immunogens.
An infection with the SARS-CoV-2 can lead to a respiratory syndrome called Corona Virus Disease 2019 (COVID-19). It was emerging in subjects since the end of 2019 in the province of Hubei, China, and rapidly spreading with a pandemic trend all over the world.
Subjects infected with SARS-CoV-2 may remain asymptomatic or develop only mild upper airways symptoms, like those of a cold or flu. Others develop pneumonia and ARDS requiring intubation in ICU and may undergo complications that can be fatal. It can take up to 14 days after exposure to SARS-CoV-2 before they appear. PCR tests only show a positive result if the virus is still present. The tests cannot identify subjects who have gone through an infection, recovered and have the virus from their bodies removed.
Enzyme immunoassays, on the other hand, are serological tests that allow the determination of specific antibodies to SARS-CoV-2. For a significant serological result, 2 samples from one subject should be tested, one sample at the onset of symptoms and a second sample collected about 4 weeks later.
1 x Microtiter plate (3 modules with 4 strips per 8 wells) and 2 adhesive foils
1 x Concentrated wash buffer (60 ml)
1 x Sample diluent (50 ml)
1 x Start Reagent (8 ml)
1 x Conjugate (15 ml)
1 x Substrate (15 ml)
1 x Stop solution (15 ml)
Results in under 2 hours
Three antigen targets in the same kit
98% Sensitivity, > 98% Specificity